Eight‐week oral administration of meloxicam, a non‐steroidal anti‐inflammatory drug, prevents dose reduction of pegylated interferon α‐2a in the treatment of chronic hepatitis C

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Hepatology Research

• Publication date

  2008-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1872-034X.2007.00260.xPMID 17825059
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.

  2007cited by this paper
• Treatment of Patients with Recurrent Hepatitis C after Liver Transplantation with Peginterferon Alfa-2B Plus Ribavirin

  2006cited by this paper
• Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.

  2006cited by this paper
• Increasing hepatitis C virus-associated hepatocellular carcinoma mortality and aging: Long term trends in Japan.

  2006cited by this paper
• A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE).

  2006cited by this paper
• Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

  2005cited by this paper
• Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation.

  2005cited by this paper
• Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study.

  2005cited by this paper
• The Impact of Haematopoietic Growth Factors on the Management and Efficacy of Antiviral Treatment in Patients with Hepatitis C Virus

  2005cited by this paper
• Platelet sparing effect of COX II inhibition used with pegylated interferon alfa-2a for the treatment of chronic hepatitis C: a short term pilot study.

  2004cited by this paper
• Epoetin alfa improves quality of life in anemic HCV‐infected patients receiving combination therapy

  2004cited by this paper
• Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study.

  2004cited by this paper
• Efficacy and Safety of Two-Dose Regimens of Peginterferon Alpha-2a Compared with Interferon Alpha-2a in Chronic Hepatitis C: A Multicenter, Randomized Controlled Trial

  2004cited by this paper
• Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam.

  2004cited by this paper
• Treatment of Established Recurrent Hepatitis C in Liver-Transplant Recipients with Pegylated Interferon-alfa-2b and Ribavirin Therapy

  2004cited by this paper
• Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

  2004cited by this paper
• Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus–infected patients receiving ribavirin plus interferon alfa

  2003cited by this paper
• Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data.

  2003cited by this paper
• Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection

  2003cited by this paper
• Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

  2002cited by this paper
• Risk of cardiovascular events associated with selective COX-2 inhibitors.

  2001cited by this paper
• Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin

  2001cited by this paper
• PEGINTERFERON ALFA-2a IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS PEGINTERFERON ALFA-2a IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS

  2000cited by this paper
• The past incidence of hepatitis C virus infection: Implications for the future burden of chronic liver disease in the United States

  2000cited by this paper
• Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.

  2000cited by this paper
• Peginterferon alfa-2a in patients with chronic hepatitis C.

  2000cited by this paper
• The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.

  1999cited by this paper
• Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis.

  1999cited by this paper
• Prevalence of hepatitis C virus infection in the United States.

  1999cited by this paper
• Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)

  1998cited by this paper
• [The prevalence of hepatitis C virus infection].

  1998cited by this paper
• Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

  1998cited by this paper
• Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus

  1998cited by this paper
• Combination treatment of advanced HCV associated liver disease with interferon and G-CSF.

  1995cited by this paper
• Analysis of granulocyte-macrophage progenitor cells in patients treated with recombinant interferon alpha-2.

  1985cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Clinical Study Differential Impact of Adherence to Pegylated Interferon and Ribavirin in the Treatment of Genotype 1 High Viral Titer Chronic Hepatitis

  2014cites this paper
• Meloxicam as an adjuvant to peginterferon‐α‐2a and ribavirin treatment for genotype 1 chronic hepatitis C: A randomized trial

  2013cites this paper
• Differential Impact of Adherence to Pegylated Interferon and Ribavirin in the Treatment of Genotype 1 High Viral Titer Chronic Hepatitis C

  2010cites this paper
• Recent role of splenectomy in chronic hepatic disorders

  2008cites this paper